Last reviewed · How we verify
Estradiol valerate 2 mg, cyproterone acetate 25 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Estradiol valerate 2 mg, cyproterone acetate 25 mg (Estradiol valerate 2 mg, cyproterone acetate 25 mg) — Thai Red Cross AIDS Research Centre.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Estradiol valerate 2 mg, cyproterone acetate 25 mg TARGET | Estradiol valerate 2 mg, cyproterone acetate 25 mg | Thai Red Cross AIDS Research Centre | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Estradiol valerate 2 mg, cyproterone acetate 25 mg CI watch — RSS
- Estradiol valerate 2 mg, cyproterone acetate 25 mg CI watch — Atom
- Estradiol valerate 2 mg, cyproterone acetate 25 mg CI watch — JSON
- Estradiol valerate 2 mg, cyproterone acetate 25 mg alone — RSS
Cite this brief
Drug Landscape (2026). Estradiol valerate 2 mg, cyproterone acetate 25 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/estradiol-valerate-2-mg-cyproterone-acetate-25-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab